Humana AB (HUM) AI Stock Analysis

• Market Cap: kr1.76B
• Dividend Yield: 2.63%
• Average Volume (3M): 76.28K
• Price to Earnings (P/E): 8.9
• Beta (1Y): 0.55
• Revenue Growth: 8.43%
• EPS Growth: 24.08%
• Country: SE
• Employees: 11,127
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Care Facilities
• EPS (TTM): 0.31
• Shares Outstanding: 51,826,057
• 10 Day Avg. Volume: 72,909
• 30 Day Avg. Volume: 76,281
• PEG Ratio: 0.27
• Price to Book (P/B): 0.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 2.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr45.05
• Price Target Upside: 18.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 68 Neutral
• Price Target: kr37.00 ▼(-2.63%Downside)

Humana AB's strong financial performance and attractive valuation are the primary strengths, suggesting a solid investment case. However, the technical indicators signal caution due to bearish trends and volatility, which could impact short-term price movement.

Humana AB Business Overview & Revenue Model

Company Description

Humana AB (HUM) is a leading care services company in the Nordic region, focusing on providing high-quality care for individuals in need. The company operates across several sectors, including individual and family care, personal assistance, and elderly care. Humana AB is dedicated to enhancing the quality of life for their clients through innovative and tailored care solutions that meet diverse needs and preferences.

How the Company Makes Money

Humana AB generates revenue primarily through the provision of care services across its key sectors: individual and family care, personal assistance, and elderly care. The company's revenue streams include government contracts, private pay clients, and partnerships with local municipalities who require outsourced care services. Additionally, Humana AB leverages its extensive network of facilities and trained staff to deliver personalized care, ensuring a steady flow of income from long-term care agreements and service fees. Strategic partnerships with healthcare providers and continuous investment in service innovation further contribute to the company's earnings.

Humana AB Financial Statement Overview

Summary

Humana AB demonstrates solid financial health with strong revenue growth and profitability. The company's operational efficiency is evident from its healthy margins and cash flow generation. While the balance sheet shows manageable leverage, increasing liabilities could pose future risks. Overall, the financial outlook is positive, with some areas needing attention for sustained stability.

Income Statement

Humana AB's revenue has shown consistent growth over the years, with a notable increase from 2022 to 2023. The net profit margin is solid, indicating effective cost management. However, the gross profit margin has declined, suggesting rising costs or pricing pressures. The EBIT and EBITDA margins are robust, reflecting strong operational performance.

Balance Sheet

The company's balance sheet demonstrates a moderate debt-to-equity ratio, indicating manageable leverage. The equity ratio is stable, although there is room for improvement. Return on equity is decent, showing effective use of equity to generate profits. However, total liabilities have increased over time, which could pose a risk if not managed carefully.

Cash Flow

Humana AB exhibits strong operating cash flow, consistently outpacing net income, which highlights robust cash generation capabilities. Free cash flow has grown, indicating effective capital investment strategies. However, the high capital expenditures in recent periods warrant monitoring.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.42B	10.29B	9.65B	9.20B	8.19B	7.77B
Gross Profit	534.00M	896.00M	757.00M	9.14B	8.13B	7.39B
EBITDA	1.14B	1.05B	457.00M	901.00M	892.00M	842.00M
Net Income	197.00M	144.00M	176.00M	210.00M	276.00M	262.00M
Balance Sheet
Total Assets	10.20B	10.63B	10.03B	9.81B	9.00B	8.04B
Cash, Cash Equivalents and Short-Term Investments	658.00M	583.00M	675.00M	690.00M	695.00M	759.00M
Total Debt	5.08B	5.15B	5.02B	5.40B	4.92B	4.27B
Total Liabilities	6.92B	7.33B	7.10B	7.07B	6.45B	5.69B
Stockholders Equity	3.15B	3.16B	2.89B	2.74B	2.55B	2.35B
Cash Flow
Free Cash Flow	674.00M	869.00M	451.00M	442.00M	582.00M	528.00M
Operating Cash Flow	900.00M	869.00M	621.00M	633.00M	689.00M	661.00M
Investing Cash Flow	-223.00M	-532.00M	-151.00M	-246.00M	-260.00M	-37.00M
Financing Cash Flow	-608.00M	-434.00M	-457.00M	-424.00M	-521.00M	-667.00M

Humana AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 38.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HUM, the sentiment is Negative. The current price of 38 is above the 20-day moving average (MA) of 36.91, above the 50-day MA of 36.84, and above the 200-day MA of 37.89, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 33.36 is Neutral, neither overbought nor oversold. The STOCH value of 70.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:HUM.

Humana AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMBEA	78 Outperform	kr9.36B	15.97	12.49%	1.86%	5.86%	33.17%
HUM	68 Neutral	kr1.76B	8.92	6.38%	2.63%	8.43%	24.08%
CAT.B	54 Neutral	kr2.60B	96.88	-9.35%	3.04%	-2.63%	-1491.39%
Sector *	52 Neutral	$7.34B	-0.07	-63.86%	2.36%	16.17%	0.23%
FLERIE	50 Neutral	kr3.47B	0.29	-15.21%	―	-75.91%	―

Humana AB Corporate Events

Humana AB Reports Strong Half-Year Results and Strategic Financial Moves

Humana AB reported its second quarter and half-year 2025 results, highlighting a net revenue of SEK 2,506 million for the quarter and SEK 5,039 million for the half-year. The company experienced a slight decline in organic growth but improved its net profit after tax and free cash flow. Significant events included a share buyback program and a new loan agreement aimed at reducing interest expenses, which positions the company for future growth and profitability.

The most recent analyst rating on (SE:HUM) stock is a Buy with a SEK50.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana AB Reduces Financing Costs with New Loan Agreement

Humana AB has signed a new long-term loan agreement to refinance existing loans, amounting to approximately SEK 2.3 billion. This new loan structure, involving a larger proportion of revolving variable credits and lower interest margins, is expected to reduce the company’s annual net interest income by SEK 35 million. The agreement, which includes options for extension and expansion, allows Humana to efficiently manage its cash flow and liquidity, reflecting a strengthened financial position. The new financing will replace the current loan, positioning Humana to continue its operations effectively.

The most recent analyst rating on (SE:HUM) stock is a Buy with a SEK42.00 price target. To see the full list of analyst forecasts on Humana AB stock, see the SE:HUM Stock Forecast page.

Humana AB Completes Share Repurchase Program

Humana AB has completed a share repurchase program, buying back a total of 985,273 shares as part of a strategy to improve its capital structure. This buy-back, conducted on Nasdaq Stockholm, reflects Humana’s commitment to optimizing shareholder value and aligns with regulatory standards, potentially impacting its market positioning and stakeholder interests.

Humana AB AGM Approves Key Resolutions and Strategic Authorizations

During its Annual General Meeting, Humana AB approved several key resolutions, including the adoption of financial statements for 2024, a dividend payout of SEK 1.00 per share, and the re-election of board members. The company also authorized the board to issue new shares and manage the acquisition and transfer of its own shares, aiming to enhance capital structure and flexibility for future acquisitions.

Humana AB Advances Share Buy-Back Program

Humana AB has repurchased 133,586 of its own shares as part of a buy-back program aimed at improving its capital structure. This initiative, which allows for the repurchase of up to 1,000,000 shares, is conducted in compliance with EU regulations and reflects the company’s strategic focus on enhancing shareholder value.